In the long aftermath of a pandemic that has left millions still unwell, researchers at the University of California, San Francisco have surfaced a quiet but consequential question: could an existing antiviral drug offer relief to those trapped in the chronic limbo of long COVID? Three carefully documented cases suggest that Paxlovid, already approved for acute infection, may ease the persistent symptoms that afflict roughly 30 percent of those who contract the virus — a possibility that, if confirmed, would carry profound implications for public health. The evidence is not yet proof, but it i
Reuters
· May 05, 2022
· health
· 2 min de lectura
High
Verificación: Verificado
Researchers call for clinical trials of Paxlovid for long COVID
Long COVID affects approximately 30% of infected individuals, causing debilitating symptoms including fatigue, brain fog, and chronic pain that can prevent people from working.
◉
Health & Medicine
8098 artículos relacionados
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% coincidencia
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% coincidencia
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% coincidencia
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% coincidencia
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% coincidencia
Cobertura Relacionada
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Sesgo y Encuadre
⚖
Reuters reports on UCSF researchers' case studies suggesting Paxlovid may help long COVID patients, presenting preliminary evidence while appropriately calling for formal clinical trials.
Bias Direction
center
Confidence
HIGH
Evidence-based reporting with cautious optimism. The article frames Paxlovid as a potential treatment avenue while maintaining appropriate scientific skepticism by emphasizing the need for clinical trials and presenting a counterexample where the drug's benefits were temporary.
fresh impetus
debilitating condition
a lot of hope
Perspectives from patients who took Paxlovid for long COVID without symptom improvement
Commentary from independent researchers not affiliated with UCSF
Potential side effects or risks of Paxlovid use in long COVID patients
Cost and accessibility concerns for long COVID patients
Perspectives from Pfizer or other pharmaceutical industry stakeholders
Impacto Geopolítico
🌎
UCSF researchers present preliminary evidence supporting clinical trials of Paxlovid for long COVID treatment, with minimal geopolitical implications but potential pharmaceutical market and healthcare policy impacts.
Escalation Risk
low
Confidence
HIGH
No significant geopolitical power shifts. Domestic U.S. healthcare policy and Pfizer's market position may be affected by trial outcomes; potential influence on global pharmaceutical treatment standards.
Lente Económico
📈
UCSF researchers present preliminary evidence supporting clinical trials of Pfizer's Paxlovid for long COVID treatment, potentially expanding the drug's market addressable population and revenue opportunities.
Market Signal
bullish
Confidence
MED
Pharmaceuticals
Healthcare Services
Medical Research
Biotechnology
Long COVID patients could gain access to a potential treatment for a debilitating condition affecting ~30% of COVID-infected individuals, reducing lost productivity and healthcare costs. However, benefits remain unproven pending clinical trials.
FDA may expand Paxlovid's approved indications beyond acute COVID if trials succeed, potentially broadening insurance coverage and reimbursement. Healthcare systems may need to allocate resources for long COVID treatment protocols. Public health agencies may revise treatment guidelines.